Navigation Links
QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lilly's Investigational Cancer Compounds
Date:11/18/2013

general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).


Contacts:

Public Relations:
Dr. Thomas Theuringer                    
Director Public Relations                    
+49-2103-29-11826
+1-240-686-7425
Email: pr@qiagen.com

http://www.twitter.com/qiagen

http://www.qiagen.com/About-Us/Press-and-Media/

Investor Relations:
John Gilardi
VP Corporate and Investor Relations
+49-2103-29-11711
Email: pr@qiagen.com


'/>"/>
SOURCE Qiagen N.V.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
2. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
3. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
4. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
5. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
6. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
7. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
8. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
9. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
10. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
11. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... FRANCISCO , March 3, 2015 Kindred Biosciences, ... on saving and improving the lives of pets, announced today ... financial results on March 12, 2015 after the market close. ... Eastern Time that day. Interested parties may ... US, or (484) 756-4262 internationally, and using conference ID 98449349.  ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research and ... addition of Jain PharmaBiotech,s new report "RNAi - ... , Because of its ability to silence ... been adopted as the research tool to discriminate gene ... RNAi can be designed to target every gene in ...
(Date:3/3/2015)... March 3, 2015  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... with a focus on protecting the microbiome, announced today that ... present at the 27th Annual ROTH Conference being held on ... in Dana Point, CA. ... 2015 at 1:00 p.m. (Pacific Time). A live ...
(Date:3/2/2015)... PA (PRWEB) March 02, 2015 The ... ReachMD announced today the launch of ... to educate healthcare professionals on the application of human ... The series features peer-to-peer interviews conducted during the ASHG ... ,     Translational Genomics and Health Outcomes Research: What's ...
Breaking Biology Technology:Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 2Global RNAi Market Report 2015 - Technologies, Markets and Companies 2014-2024 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 2American Society of Human Genetics (ASHG) and ReachMD Launch Series on Genetics and Genomics 3
... Conference Call at 10:30 a.m. ET, May 13 -, ... NTII ) today announced financial,results for its fiscal third quarter ... the three months ended March 31, 2008 were $3.7 million,compared ... Research and development expenses were $5.9 million for the ...
... DIEGO, May 12 Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ... Conference,on Wednesday, May 14, 2008 at 3:05 p.m. CT ... Vice President, Finance and Chief Financial Officer of,Amylin Pharmaceuticals, ... presentation and breakout session will be webcast, and a,recording ...
... How To Stop The Food Riots. (Atlantic and Latin ... on the,world food crisis with a primer on the ... of control, the worry is that millions more of,the ... Over the past few,months, there have been food-related riots ...
Cached Biology Technology:Neurobiological Technologies Reports Third Quarter Financial Results 2Neurobiological Technologies Reports Third Quarter Financial Results 3Neurobiological Technologies Reports Third Quarter Financial Results 4Neurobiological Technologies Reports Third Quarter Financial Results 5Newsweek International Editions: Highlights And Exclusives, May 19, 2008 2Newsweek International Editions: Highlights And Exclusives, May 19, 2008 3Newsweek International Editions: Highlights And Exclusives, May 19, 2008 4Newsweek International Editions: Highlights And Exclusives, May 19, 2008 5
(Date:2/18/2015)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. , Cowen and ... Tuesday, March 3, 2015 at 11.20 a.m. Eastern Time ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern ... webcasts for these events, please visit Cepheid,s website at ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... health benefits of consuming dark chocolate and cocoa mounts, ... and chocolate products deliver the most beneficial compounds, known ... production diminish the levels of cocoa flavanols. ... the effect of conventional production methods of cocoa beans ...
... Orleans, LA LSU oncologist Vince D. Cataldo, MD, ... two chemotherapy drugs now indicated for second and third-line ... remarkably effective in treating a certain subset of these ... at LSU Health Sciences Center New Orleans School of ...
... Montreal, QC March 10, 2011 In childhood, boys and ... peers. Around early adolescence, they gradually begin to include ... in Journal of Research on Adolescence suggests ... The findings show that girls tend to initiate the ...
Cached Biology News:Study clarifies the role of cocoa bean handling on flavanol levels 2Study shows new treatment strategy effective for certain lung cancers 2Early male friendship as a precursor to substance abuse in girls 2
Monoclonal antibodies conjugated with rhodamine...
... [RET-P1] to Rhodopsin Rhodopsin is a ... mammals, birds, amphibians, and reptiles. The rhodopsin ... in the retina. Immunogen: ... Specificity: This antibody specifically labels ...
... 3′-(α-Amino- p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl ... FROM MOISTURE. Protein synthesis inhibitor. Inhibits ... nascent polypeptide chains. Induces DNA fragmentation ... leukemia cells. Purity: ≥98% by ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: